Chiesi Farmaceutici SpA And Novartis Pharma AG (NVS) Sign International Licensing Agreement For Formoterol Modulite® HFA
10/19/2005 5:12:34 PM
Chiesi Farmaceutici S.p.A. and Novartis Pharma AG have signed an international licensing and supply agreement for Chiesi’s Formoterol Modulite®, an HFA-based pressurised metered-dose inhaler (pMDI) product. Under the agreement, Novartis will have semi-exclusive promotion, sales and distribution rights for the product, following approval, in Denmark, France, Germany, Greece, Netherlands, Republic of South Africa, Spain, Switzerland and Turkey. Chiesi will supply Novartis with the finished product. A previous agreement for commercialisation of the product in Italy was signed last year.
comments powered by